Dabrafenib + Trametinib in Patients w/rare BRAF V600E Mutated Solid Tumor (CDRB436IIC01) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to collect information about how well dabrafenib plus trametinib works in patients who have unresectable (cannot be removed by surgery) or metastatic BRAF V600E mutation positive solid tumors.
What is the Condition Being Studied?
Unresectable or Metastatic BRAF V600E Mutation Positive Solid Tumors
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with unresectable or metastatic BRAF V600E mutation positive solid tumors
- Have not received dabrafenib-trametinib previously for your disease or have not received it for more than one year for any other malignancy
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.
Age Group
Adults
What is Involved?
If you choose to join this study, we will collect information related to your cancer and treatment and enter it into a database that we will keep indefinitely. This information will help us better understand how the drug combination works for people who have this rare mutation.
Study Details
Full Title
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00113811
NCT:
NCT05868629
Phase
Phase
IV
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment